Table 1.
Summary of study demographics
| Author | Year | Recurrent disease included? | Patient cohort (n) |
Mean age (yr) |
Median follow-up (mo) |
Surveillance modality | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| PDD | WL | PDD | WL | PDD | WL | |||||
| HAL | Hermann [23] | 2011 | Yes | 59 | 74 | 71 | 69 | 12 | 12 | WL |
| Geavlete [24] | 2012 | Yes | 125 | 114 | 66.8 | 24 | 24 | WL | ||
| Karaolides [25] | 2012 | Yes | 41 | 45 | 66.3 | 63.8 | 17 (6–25) | 14 (4.5–25) | WL | |
| O’Brien [17] | 2013 | No | 97 | 88 | 68 | 68 | 12 | 12 | Not stated | |
| Gkritsios [26] | 2014 | Yes | 48 | 37 | 66 | 68.2 | 40 | 40 | Not stated | |
| Drăgoescu [27] | 2017 | No | 57 | 56 | 59.4 | 60.3 | 71.8 a | 72.3 a | WL | |
| 5-ALA | Filbeck [14] | 2002 | Yes | 88 | 103 | 68 b | 70 b | 21 (3–30) | 21 (4–40) | WL |
| Babjuk [28] | 2005 | Yes | 60 | 62 | 67.9 | 69.8 | 22.4 a | 20.7 a | WL | |
| Daniltchenko [29] | 2005 | Not stated | 51 | 51 | 70 | 67 | 42 (25–61) | 39 (23–61) | Not stated | |
| Schumacher [30] | 2010 | Yes | 141 | 138 | 70.1 | 68.9 | 12 | 12 | WL | |
| Stenzl [31] | 2011 | Yes | 183 | 176 | 66 | 12 | 12 | WL | ||
| Rolevich [32] | 2017 | Yes | 174 | 203 | 67 | 67 | 54 | 65 | WL | |
5-ALA = 5-aminolaevulinic acid; HAL = hexaminolaevulinate; PDD = photodynamic diagnosis; WL = white light.
a
Mean.
b
Median.